Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines: Basic principles of pain management in acquired brain injury. Recommendations of the Spanish Society of Neurorehabilitation.

Neurologia·2025
Same author

[Cardiovascular safety of new drugs for the acute and preventive treatment of migraine: gepants and ditans].

Revista de neurologia·2023
Same author

[Clinical experience in the treatment of motor fluctuations in Parkinson's disease. Delphi consensus of a group of experts in movement disorders].

Revista de neurologia·2020
Same author

[Eslicarbazepine in patients with hipercholesterolemia associated to carbamazepine and oxcarbacepine].

Revista de neurologia·2016
Same author

Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid.

Neurologia·2016
Same author

[Efficacy of lacosamide in the treatment of neuropathic pain].

Revista de neurologia·2013
Same journal

The Correlation Between and Variability of Three Balance Scales in the Assessment of Balance Function in Patients With Ataxia.

Revista de neurologia·2026
Same journal

Surgical Treatment of an Aneurysm in the Subacute Stage of Hemorrhagic Moyamoya Disease: Aneurysm Resection Combined With STA-MCA Bypass: A Case Report.

Revista de neurologia·2026
Same journal

Mapping the Evidence: Central Sleep Apnea Syndromes During Sleep and Stroke-A Scoping Review.

Revista de neurologia·2026
Same journal

Developmental and Epileptic Encephalopathy Due to a Novel <i>ARHGEF9</i> Deletion Variant: Case Series of Two Siblings.

Revista de neurologia·2026
Same journal

P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.

Revista de neurologia·2026
Same journal

[Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache].

Revista de neurologia·2026
See all related articles

Related Experiment Video

Updated: Jul 7, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

[Zonisamide in refractory essential tremor].

P E Bermejo1, C Ruiz-Huete, R Dorado

  • 1Unidad de Trastornos del Movimiento Sanatorio Nuestra Senora del Rosario, Hospital de Zarzuela, 28006 Madrid, Espana. pedro_bermejo@hotmail.com

Revista De Neurologia
|February 26, 2008
PubMed
Summary
This summary is machine-generated.

Zonisamide shows promise for treating essential tremor when other medications fail. This study found it effective and well-tolerated in patients with essential tremor.

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Jul 7, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Area of Science:

  • Neurology
  • Movement Disorders
  • Pharmacology

Background:

  • Essential tremor is a common movement disorder causing action and postural tremor.
  • Current treatments like propranolol and primidone have limited efficacy and adverse effects.
  • Newer antiepileptic drugs are being explored for essential tremor treatment.

Purpose of the Study:

  • To assess the efficacy and tolerability of zonisamide for essential tremor.
  • To evaluate zonisamide as a treatment option for refractory essential tremor cases.

Main Methods:

  • Retrospective study of 13 patients with essential tremor refractory to multiple drugs.
  • Collected data included zonisamide dosage, adverse events, and treatment response.
  • Average zonisamide dosage was 215 mg/day over a 121-day treatment period.

Main Results:

  • Nine out of 13 patients (approximately 69%) showed a good response to zonisamide.
  • Response was defined by reduced daily activity limitations and improved neurological exams.
  • Zonisamide was well-tolerated, with no study dropouts due to adverse events.

Conclusions:

  • Zonisamide appears to be an effective and well-tolerated treatment for essential tremor.
  • Further placebo-controlled, larger studies are needed to confirm these findings.